Stoke Therapeutics: 3 Key Takeaways for Long-Term Investors
Key PointsThe FDA agreed to a multicomponent assessment using four subdomains for the key secondary endpoint on cognition and behavior.
1. Stoke Therapeutics (STOK) has secured alignment with the FDA on a composite endpoint for their lead drug candidate, Zorevunersen, specifically for treating Dravet syndrome. This agreement confirms the approval pathway for the experimental medicine, targeting a rare genetic epilepsy with high unmet medical need, and strengthens prospects for potential approval and launch in early 2028.
2. The New Drug Application (NDA) submission for Zorevunersen will incorporate a combined cognitive and behavioral assessment. The FDA has agreed to evaluate key secondary endpoints using four subdomains from the Vineland-3, an adaptive behavior scale, which will provide a multicomponent assessment of cognitive and behavioral changes.
3. The EMPEROR Phase III registrational trial enrolled 162 patients without any discontinuations, signaling strong caregiver commitment to the clinical program. Management identifies over 6,000 addressable pediatric patients in the U.S. living with Dravet syndrome, with approximately half receiving treatment at 50 specialized medical centers experienced in intrathecal delivery.
These centers, which make up over half of the identified U.S. sites, have participated in a Zorevunersen study. Cash reserves of $358.8 million and reimbursements from Biogen will fund operations into early 2028, providing multiyear funding through the expected commercial launch.
Rewritten by urgent.news; may contain errors — check the original.
Sources: fool.com · nasdaq.com
This story
This is one outlet's version. Read the fullest account.